Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
Abstract Background Currently, anticancer immunotherapy based on PD‐1/PD‐L1 blockade with immune checkpoint inhibitors (ICIs) is being used as a standard therapy for non‐small cell lung cancer (NSCLC). However, more effective treatments are required as these tumors are often resistant and refractory...
Main Authors: | Shuhei Teranishi, Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Sousuke Kubo, Yuji Shibata, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-04-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13351 |
Similar Items
-
DNA Dissipative System for Controlled Release of Immunostimulatory CpG Oligodeoxynucleotides
by: Aman Ishaqat, et al.
Published: (2024-11-01) -
CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
by: Hanagata N
Published: (2017-01-01) -
INFLUENCE OF CpG ODN 2006 OLIGODEOXYNUCLEOTIDE ON CYTOKINE PRODUCTION BY BLOOD CELLS OF HUMANS VACCINATED AGAINST PLAGUE
by: S. N. Klyueva, et al.
Published: (2015-01-01) -
Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner
by: Rena Ikeda, et al.
Published: (2024-11-01) -
Immunostimulatory Effects of Guanine-Quadruplex Topologies as Scaffolds for CpG Oligodeoxynucleotides
by: Soumitra Pathak, et al.
Published: (2025-01-01)